Management of patent ductus arteriosus: a comparison of operative v pharmacologic treatment

S B Palder1, M Z Schwartz, K R Tyson

  • 1Department of Surgery, University of California, Davis Medical Center, Sacramento 95817.

Insights

Surgical ligation offers predictable results for premature infants with patent ductus arteriosus (PDA). This method shows low morbidity and no mortality, making it the preferred treatment for infants under 800g.

Area of Science:

  • Neonatalogy
  • Pediatric Cardiology
  • Surgical Innovation

Background:

  • Patent ductus arteriosus (PDA) is a common condition in premature infants.
  • Hemodynamically significant PDA can lead to cardiopulmonary compromise.
  • Treatment options include pharmacologic and surgical interventions.

Purpose of the Study:

  • To compare the efficacy and outcomes of surgical ligation versus indomethacin for hemodynamically significant PDA in premature infants.
  • To determine the preferred treatment modality for low-birth-weight premature infants.

Main Methods:

  • Retrospective review of 183 premature infants with hemodynamically significant PDA over a 5-year period.
  • Infants were treated with either surgical ligation (107) or indomethacin (76).
  • Outcomes including treatment failure, complications, and mortality were analyzed.

Main Results:

  • Surgical ligation had no treatment failures and one complication.
  • Indomethacin therapy failed in 42% of infants, with 84% requiring subsequent surgery.
  • Infants who failed indomethacin generally had lower birth weights, shorter gestations, and required prolonged ventilation.
  • No deaths were directly attributable to either treatment modality.

Conclusions:

  • Surgical ligation of PDA provides predictable outcomes with low morbidity and no mortality.
  • Surgical ligation is the preferred treatment for premature infants weighing less than 800 grams.
  • Indomethacin therapy has a significant failure rate, often necessitating surgical intervention.

Related Concept Videos

Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...